Genentech/Roche, Drug Prices & Medicare Spending

Genentech/Roche manufactures 22 drugs tracked by Medicare Part D with total spending of $17.0B.

Drugs Tracked

$17.0B

Medicare Spending

$1,447.90

Avg Cost/Claim

100%

Have Generics

Genentech/Roche Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Ocrevus	Ocrelizumab	$23,635.00	$3.5B	+16.5%	Yes
2	Tecentriq	Atezolizumab	$10,847.00	$1.3B	+12.8%	Yes
3	Vabysmo	Faricimab	$663.00	$1.2B	+156.3%	Yes
4	Perjeta	Pertuzumab	$12,592.00	$1.2B	-5.6%	Yes
5	Hemlibra	Emicizumab	$34,278.00	$1.2B	+18.6%	Yes
6	Lucentis	Ranibizumab	$654.00	$1.1B	-22.3%	Yes
7	Kadcyla	Ado-Trastuzumab Emtansine	$14,515.00	$987.0M	-8.2%	Yes
8	Actemra	Tocilizumab	$5,306.00	$987.0M	+6.2%	Yes
9	Rituxan	Rituximab	$3,980.00	$987.0M	-18.6%	Yes
10	Alecensa	Alectinib	$12,882.00	$876.0M	+12.4%	Yes
11	Gazyva	Obinutuzumab	$11,813.00	$567.0M	+4.2%	Yes
12	Evrysdi	Risdiplam	$31,500.00	$567.0M	+42.6%	Yes
13	Avastin	Bevacizumab	$3,831.00	$567.0M	-22.4%	Yes
14	Herceptin	Trastuzumab	$3,677.00	$456.0M	-28.6%	Yes
15	CellCept	Mycophenolate Mofetil	$139.00	$345.0M	-18.6%	Yes
16	Oseltamivir	Oseltamivir Phosphate	$72.00	$178.0M	+12.4%	Yes
17	Tarceva	Erlotinib	$7,417.00	$178.0M	-24.4%	Yes
18	Rozlytrek	Entrectinib	$14,833.00	$178.0M	+18.6%	Yes
19	Gavreto	Pralsetinib	$14,833.00	$178.0M	+28.4%	Yes
20	Zelboraf	Vemurafenib	$10,250.00	$123.0M	-14.6%	Yes
21	Cotellic	Cobimetinib	$10,250.00	$123.0M	-8.4%	Yes
22	Ibandronate	Ibandronate Sodium	$36.00	$67.0M	-28.6%	Yes

Frequently Asked Questions

Genentech/Roche manufactures 22 drugs tracked by Medicare Part D, with total annual spending of $17.0B.

Hemlibra (Emicizumab) is the most expensive at $34,278.00 per claim.

22 of 22 Genentech/Roche drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.